

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

**FLEXIROAM LIMITED**

ABN

**27 143 777 397**

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |   |  |  |
|---|--|--|
| 1 | +Class of +securities issued or to be issued   | <b>Performance rights</b>  |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | <b>2,700,000</b>   |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <b>Exercise price: nil.<br/>Vesting date: 31 March 2017.<br/>Vesting conditions:<br/>The Company must achieve a revenue target of AUD\$12,000,000 for the financial year ending 31 March 2017 and Mr Jeffrey Ong must remain in continuous employment as the Company's Chief Executive Officer until the vesting date.</b> |

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p><b>No.</b></p> <p><b>Performance Rights are not quoted securities and do not rank equally with ordinary shares or any other class of quoted securities. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder. Any ordinary share issued to the holder of a Performance Right upon vesting will rank equally from the date of allotment with other ordinary shares.</b></p>
<p>5 Issue price or consideration</p>	<p><b>The recipient was not required to pay for the grant of the Performance Rights and for each Performance Right that vests, the recipient will be entitled to receive one share in the Company without payment.</b></p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p><b>As approved at the Company's Annual General Meeting held on 29 August 2016, the Performance Rights were issued pursuant to the Company's Performance Rights Plan as part of the remuneration package of the Company's Chief Executive Officer, Mr Jeffrey Ong.</b></p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p><b>Yes</b></p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p><b>29 August 2016</b></p>
<p>6c Number of +securities issued without security holder approval under rule 7.1</p>	<p><b>Nil</b></p>
<p>6d Number of +securities issued with security holder approval under rule 7.1A</p>	<p><b>Nil</b></p>

---

+ See chapter 19 for defined terms.

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<b>2,700,000 Performance Rights – shareholder meeting held on 29 August 2016.</b>									
6f	Number of securities issued under an exception in rule 7.2	<b>Nil</b>									
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	<b>Not applicable</b>									
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	<b>Not applicable</b>									
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	<b>7.1 – 29,053,425</b> <b>7.1A – 19,368,950</b>									
7	+Issue dates <small>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</small>	<b>6 September 2016.</b>									
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th>Number</th> <th>+Class</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">65,938,101</td> <td>Fully paid ordinary shares.</td> </tr> <tr> <td style="text-align: center;">2,276,400</td> <td>Fully paid ordinary shares escrowed until 29 January 2018</td> </tr> </tbody> </table>	Number	+Class	65,938,101	Fully paid ordinary shares.	2,276,400	Fully paid ordinary shares escrowed until 29 January 2018			
Number	+Class										
65,938,101	Fully paid ordinary shares.										
2,276,400	Fully paid ordinary shares escrowed until 29 January 2018										
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th>Number</th> <th>+Class</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">125,475,000</td> <td>Fully paid ordinary shares escrowed until 16 June 2017.</td> </tr> <tr> <td style="text-align: center;">3,000,000</td> <td>Options exercisable at \$0.20 each on or before 8 June 2018.</td> </tr> <tr> <td style="text-align: center;">2,700,000</td> <td>Performance Rights.</td> </tr> </tbody> </table>	Number	+Class	125,475,000	Fully paid ordinary shares escrowed until 16 June 2017.	3,000,000	Options exercisable at \$0.20 each on or before 8 June 2018.	2,700,000	Performance Rights.	
Number	+Class										
125,475,000	Fully paid ordinary shares escrowed until 16 June 2017.										
3,000,000	Options exercisable at \$0.20 each on or before 8 June 2018.										
2,700,000	Performance Rights.										
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	<b>Performance Rights do not confer a right to receive dividends.</b>									

+ See chapter 19 for defined terms.

## Part 2 - Bonus issue or pro rata issue

*Questions 11 to 33 Not Applicable*

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1.

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Questions 35 to 37 - Not Applicable*

### Entities that have ticked box 34(b)

*Questions 38 to 42 - Not Applicable*

**Quotation agreement**

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.  
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: **6 September 2016**

(Company Secretary)

Print name: **Kim Hogg**

== == == == ==

---

+ See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

### Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

#### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>					
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>					
<b>Insert</b> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	188,197,501				
<p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 <table style="margin-left: 20px;"> <tr> <td style="text-align: right;">2,792,000</td> <td style="text-align: right;">29 Jan 2016</td> </tr> <tr> <td style="text-align: right;">2,700,000</td> <td style="text-align: right;">5 Apr 2016</td> </tr> </table> </li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	2,792,000	29 Jan 2016	2,700,000	5 Apr 2016	
2,792,000	29 Jan 2016				
2,700,000	5 Apr 2016				
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil				
<b>“A”</b>	<b>193,689,501</b>				

+ See chapter 19 for defined terms.

<b>Step 2: Calculate 15% of “A”</b>	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	<b>29,053,425</b>
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	Nil
“C”	Nil
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
“A” x 0.15 <i>Note: number must be same as shown in Step 2</i>	<b>29,053,425</b>
<b>Subtract “C”</b> <i>Note: number must be same as shown in Step 3</i>	Nil
<b>Total [“A” x 0.15] – “C”</b>	<b>29,053,425</b> <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	<b>193,689,501</b>
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10 <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	<b>19,368,950</b>
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• This applies to equity securities – not just ordinary securities</li> <li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Nil
<b>“E”</b>	Nil
<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
<b>“A” x 0.10</b> <i>Note: number must be same as shown in Step 2</i>	<b>19,368,950</b>
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	<b>Nil</b>
<b>Total [“A” x 0.10] – “E”</b>	<b>19,368,950</b> <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.